ReShape Lifesciences OverviewReShape Lifesciences EBIT
EBIT (Earnings Before Interest and Taxes) analysis for RSLS.
Quarterly EBIT
-$1.13M
↑ 38.7% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$11.24M
↓ 78.46% YoY
Trailing 12 months ending Mar 31, 2026
ReShape Lifesciences OverviewEBIT (Earnings Before Interest and Taxes) analysis for RSLS.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026